

Substitute for form 1449B/PTO

**SIXTH SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
IN AN APPLICATION**
**LISTING OF REFERENCES**
**JUNE 5, 2008**

(Use several sheets if necessary)

ATTORNEY DOCKET NO.

3022.1004-000

APPLICATION NO.

10/088,677

FIRST NAMED INVENTOR

Joerg Schneider

371(c) DATE

May 31, 2002

EXAMINER

Robert A. Zeman

CONFIRMATION NO.

4825

GROUP

1645


**U.S. PATENT DOCUMENTS**

EXAM- -INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A21	6,355,252 B1	03-12-2002	Smith, <i>et al.</i>
	A22	7,273,605	09-25-2007	Laidlaw, <i>et al.</i>
	A23	2001/0036928 A1	11-01-2001	Chamberlain, <i>et al.</i>
	A24	2004/0142002	07-22-2004	Smith, <i>et al.</i>

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	B18	WO 99/41383 A1	08-19-1999	Maxygen, Inc.		
	B19	WO 02/24224 A2	03-28-2002	Oxxon Pharmaccines Limited		
	B20	WO 2005/026370 A2	03-24-2005	Aventis Pasteur Limited and Therion Biologics, Inc.		
	B21	WO 2006/061643 A1	06-15-2006	Oxxon Therapeutics Limited		
	B22	WO 2006/120474 A2	11-16-2006	Oxxon Therapeutics Limited		
	B23	WO 2006/125983 A1	11-30-2006	Oxxon Therapeutics Limited		
	B24	CN 1 324 661 A	12-05-2001	Second Military Medical University, PLA		X

EXAMINER

DATE CONSIDERED

Substitute for form 1449B/PTO  <b>SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>JUNE 5, 2008</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677
	FIRST NAMED INVENTOR Joerg Schneider		371(c) DATE May 31, 2002
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
C13	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Merck & Co., Inc. [Date signed by Opponent: Feb. 9, 2006 ; Date filed in EPO: Feb. 13, 2006]
C14	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Crucell Holland B.V. [Date signed by Opponent: Feb. 6, 2006 ; Date filed in EPO: Feb. 13, 2006]
C15	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416. Opponent: Transgene S.A. (English translation attached.) [Date signed by Opponent: Feb. 3, 2006 ; Date filed in EPO: Feb. 6, 2006]
C26	The Chamberlain Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]
C27	The Gritz Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003].
C28	The Schlom Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Declarant: Sept. 24, 2003; Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]
C227	Anderson, R., "Treatment of Melanoma by Heterologous PrimeBoost Immunotherapy," Oxxon Therapeutics, TVLN Presentation given on April 6, 2006 (17 pages).
C228	Chow, Y-H., <i>et al.</i> , "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> , 71(1): 169-178 (1997).
C229	Haigwood, N.L., "Predictive Value of Primate Models for AIDS," <i>AIDS Reviews</i> 6:187-198 (2004).
C230	Hutchings, C.L., <i>et al.</i> , "Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity," <i>J. Immunol.</i> , 175:599-606 (2005).
C231	Lindsey, K.R., <i>et al.</i> , "Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 12(8): 2526-2537 (2006).
C232	Marshall, J.L., <i>et al.</i> , "Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses," <i>J. Clin. Oncol.</i> , 18(23): 3964-3973 (2000).
C233	Rosenberg, S.A., <i>et al.</i> , Recombinant Fowlpox Viruses Encoding the Anchor-Modified gp100 Melanoma Antigen can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 9(8): 2973-2980 (2003).
C234	Tagawa, S.T., <i>et al.</i> , "Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma," <i>Cancer</i> , 98(1): 144-154 (2003).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO  <b>SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>JUNE 5, 2008</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677
	FIRST NAMED INVENTOR Joerg Schneider		371(c) DATE May 31, 2002
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C235	Tomiyama, H., <i>et al.</i> , "Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Cytolytic Activity and Cytokine Production," <i>J. Virol.</i> , 76(15): 7535-7543 (2002).	
C236	van Baren, N., <i>et al.</i> , "Tumoral and Immunologic Response After Vaccination of Melanoma Patients with an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells," <i>J. Clin. Oncol.</i> , 23(35): 9008-9021(2005).	
C237	Vuola, J.M., <i>et al.</i> , "Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers," <i>J. Immunol.</i> , 174(1): 449-455 (2005).	
C238	Wang, X., <i>et al.</i> , "Cellular Immune Responses to Helper-Free HSV-1 Amplicon Particles Encoding HIV-1 gp120 are Enhanced by DNA Priming," <i>Vaccine</i> , 21(19-20): 2288-2297 (2003).	
C239	Woodberry, T., <i>et al.</i> , "Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection and Th1 Bias," <i>J. Immunol.</i> , 170:2599-2604 (2003).	
C240	Zajac, P., <i>et al.</i> , "Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients," <i>Human Gene Therapy</i> , 14(16): 1497-1510 (2003).	

EXAMINER	DATE CONSIDERED
----------	-----------------